Lavacca A, Presta R, Gai C, Mella A, Gallo E, Camussi G, et al. Early effects of first-line treatment with anti-interleukin-6 receptor antibody tocilizumab for chronic active antibody-mediated rejection in kidney transplantation. Clin Transplant. 2020;34(8): e13908.

Article  CAS  PubMed  Google Scholar 

Choi J, Aubert O, Vo A, Loupy A, Haas M, Puliyanda D, et al. Assessment of tocilizumab (anti-interleukin-6 receptor monoclonal) as a potential treatment for chronic antibody-mediated rejection and transplant glomerulopathy in HLA-sensitized renal allograft recipients. Am J Transplant. 2017;17(9):2381–9.

Article  CAS  PubMed  Google Scholar 

Massat M, Congy-Jolivet N, Hebral AL, Esposito L, Marion O, Delas A, et al. Do anti-IL-6R blockers have a beneficial effect in the treatment of antibody-mediated rejection resistant to standard therapy after kidney transplantation? Am J Transplant. 2021;21(4):1641–9.

Article  CAS  PubMed  Google Scholar 

Shin BH, Everly MJ, Zhang H, Choi J, Vo A, Zhang X, et al. Impact of tocilizumab (anti-IL-6R) treatment on immunoglobulins and anti-HLA antibodies in kidney transplant patients with chronic antibody-mediated rejection. Transplantation. 2020;104(4):856–63.

Article  CAS  PubMed  Google Scholar 

Chandran S, Leung J, Hu C, Laszik ZG, Tang Q, Vincenti FG. Interleukin-6 blockade with tocilizumab increases Tregs and reduces T effector cytokines in renal graft inflammation: a randomized controlled trial. Am J Transplant. 2021;21(7):2543–54.

Article  CAS  PubMed  Google Scholar 

Pottebaum AA, Venkatachalam K, Liu C, Brennan DC, Murad H, Malone AF, et al. Efficacy and safety of tocilizumab in the treatment of acute active antibody-mediated rejection in kidney transplant recipients. Transplant Direct. 2020;6(4): e543.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Noble J, Giovannini D, Laamech R, Imerzoukene F, Janbon B, Marchesi L, et al. Tocilizumab in the treatment of chronic antibody-mediated rejection post kidney transplantation: clinical and histological monitoring. Front Med (Lausanne). 2021;8: 790547.

Article  PubMed  PubMed Central  Google Scholar 

Khairallah P, Robbins-Juarez S, Patel S, Shah V, Toma K, Fernandez H, et al. Tocilizumab for the treatment of chronic antibody mediated rejection in kidney transplant recipients. Clin Transplant. 2023;37(1): e14853.

Article  CAS  PubMed  Google Scholar 

Boonpheng B, De Castro ICC, Ng YH, Blosser C, Bakthavatsalam R, Gimferrer I, et al. Tocilizumab for treatment of chronic active antibody-mediated rejection in kidney transplant recipients. Clin Transplant. 2023;37(5): e14936.

Article  CAS  PubMed  Google Scholar 

European Medecines Agency. Summary of product characteristics, tocilizumab [Internet]. 2013. Disponible sur: www.ema.europa.eu/en/documents/product-information/roactemra-epar-product-information_en.pdf

Arrivé C, Jacquet M, Gautier-Veyret E, Jouve T, Noble J, Lombardo D, et al. Early exposure of kidney transplant recipients with chronic antibody-mediated rejection to tocilizumab—a preliminary study. J Clin Med. 2023;12(22):7141.

Article  PubMed  PubMed Central  Google Scholar 

Burmester GR, Rubbert-Roth A, Cantagrel A, Hall S, Leszczynski P, Feldman D, et al. A randomised, double-blind, parallel-group study of the safety and efficacy of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with moderate to severe rheumatoid arthritis (SUMMACTA study). Ann Rheum Dis. 2014;73(1):69–74.

Article  CAS  PubMed  Google Scholar 

Lauper K, Mongin D, Iannone F, Klami Kristianslund E, Kvien TK, Nordström D, et al. Comparative effectiveness of subcutaneous tocilizumab versus intravenous tocilizumab in a pan-European collaboration of registries. RMD Open. 2018;4(2): e000809.

Article  PubMed  PubMed Central  Google Scholar 

Darloy J, Segaud N, Salmon JH, Eschard JP, Goëb V, Deprez X, et al. Tocilizumab effectiveness after switching from intravenous to subcutaneous route in patients with rheumatoid arthritis: the RoSwitch study. Rheumatol Ther. 2019;6(1):61–75.

Article  PubMed  PubMed Central  Google Scholar 

Ayaz NA, Karadağ ŞG, Koç R, Demirkan FG, Çakmak F, Sönmez HE. Patient satisfaction and clinical effectiveness of switching from intravenous tocilizumab to subcutaneous tocilizumab in patients with juvenile idiopathic arthritis: an observational study. Rheumatol Int. 2020;40(7):1111–6.

Article  CAS  PubMed  Google Scholar 

Besada E. Potential patient benefit of a subcutaneous formulation of tocilizumab for the treatment of rheumatoid arthritis: a critical review. Patient Prefer Adherence. 2014;8:1051–9.

Article  PubMed  PubMed Central  Google Scholar 

Iwamoto N, Fukui S, Umeda M, Nishino A, Nakashima Y, Suzuki T, et al. Evaluation of switching from intravenous to subcutaneous formulation of tocilizumab in patients with rheumatoid arthritis. Mod Rheumatol. 2016;26(5):662–6.

Article  CAS  PubMed  Google Scholar 

Truffot A, Jouve T, Noble J, Bardy B, Malvezzi P, Rostaing L, et al. Tocilizumab trough levels variability in kidney-transplant candidates undergoing desensitization. J Clin Med. 2021;11(1):91.

Article  PubMed  PubMed Central  Google Scholar 

Willeman T, Jourdil JF, Gautier-Veyret E, Bonaz B, Stanke-Labesque F. A multiplex liquid chromatography tandem mass spectrometry method for the quantification of seven therapeutic monoclonal antibodies: application for adalimumab therapeutic drug monitoring in patients with Crohn’s disease. Anal Chim Acta. 2019;1067:63–70.

Article  CAS  PubMed  Google Scholar 

Monolix version 2023R1. Anthony, France: Lixoft SAS, 2023. https://lixoft.com/products/monolix/. Accessed 8 July 2022.

Cazaubon Y, Talineau Y, Feliu C, Konecki C, Russello J, Mathieu O, et al. Population pharmacokinetics modelling and simulation of mitotane in patients with adrenocortical carcinoma: an individualized dose regimen to target all patients at three months? Pharmaceutics. 2019;11(11):566.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cazaubon Y, Mauprivez C, Feliu C, Binet L, Oget O, Gozalo C, et al. Population pharmacokinetics of articaine with 1:200,000 epinephrine during third molar surgery and simulation of high-dose regimens. Eur J Pharm Sci. 2018;114:38–45.

Article  CAS  PubMed  Google Scholar 

Konecki C, Holm M, Djerada Z. Negative Impact of ST-segment elevation myocardial infarction and morphine dose on ticagrelor uptake and pharmacodynamics: a population PK/PD analysis of pooled individual participant data. Clin Pharmacokinet. 2023;62(6):905–20.

Article  CAS  PubMed  Google Scholar 

Dua P, Hawkins E, van der Graaf P. A tutorial on target-mediated drug disposition (TMDD) models. CPT Pharmacomet Syst Pharmacol. 2015;4(6):324–37.

Article  CAS  Google Scholar 

Samson A, Lavielle M, Mentré F. Extension of the SAEM algorithm to left-censored data in nonlinear mixed-effects model: application to HIV dynamics model. Comput Stat Data Anal. 2006;51(3):1562.

Article  Google Scholar 

Ishii-Watabe A, Kuwabara T. Biosimilarity assessment of biosimilar therapeutic monoclonal antibodies. Drug Metab Pharmacokinet. 2019;34(1):64–70.

Article  CAS  PubMed  Google Scholar 

Guideline on the investigation of bioequivalence, European Medecines Agency. 2010. Ref. : CPMP/EWP/QWP/1401/98 Rev.1/ Corr**.

R Core Team (2023). _R: A Language and environment for statistical computing_. R Foundation for Statistical Computing, Vienna, Austria.

Schropp J, Khot A, Shah DK, Koch G. Target-mediated drug disposition model for bispecific antibodies: properties, approximation, and optimal dosing strategy. CPT Pharmacomet Syst Pharmacol. 2019;8(3):177–87.

Article  CAS  Google Scholar 

Frey N, Grange S, Woodworth T. Population pharmacokinetic analysis of tocilizumab in patients with rheumatoid arthritis. J Clin Pharmacol. 2010;50(7):754–66.

Article  CAS  PubMed  Google Scholar 

Abdallah H, Hsu JC, Lu P, Fettner S, Zhang X, Douglass W, et al. Pharmacokinetic and pharmacodynamic analysis of subcutaneous tocilizumab in patients with rheumatoid arthritis from 2 randomized, controlled trials: SUMMACTA and BREVACTA. J Clin Pharmacol. 2017;57(4):459–68.

Article  CAS  PubMed  Google Scholar 

Bastida C, Ruiz-Esquide V, Pascal M, de Vries Schultink AHM, Yagüe J, Sanmartí R, et al. Fixed dosing of intravenous tocilizumab in rheumatoid arthritis. Results from a population pharmacokinetic analysis. Br J Clin Pharmacol. 2018;84(4):716–25.

Article  CAS  PubMed  PubMed Central